Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

Abstract

Lee EJ, Kim KR, Lim SK, Lee HC, Kim DI, Kim SH, Huh KB. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). Eur J Endocrinol 1994;131: 109–12. ISSN 0804–4643 We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201–995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSHsecreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor. Eun Jig Lee, Division of Endocrinology, Department of Internal Medicine, Yong Dong Severance Hospital, Youngdong PO Box 1217, Seoul 135-270, Korea